Osuga, Yutaka
No ORCID on file
· 37 papers in corpus
2024
Additional file 1. The study protocol has been approved by the Clinical Study Review Board of Chiba University Hospital, Chiba, Japan, and registered by the Japan Registry of Clinical Trials (jRCTs032230278, https://jrct.niph.go.jp/ ). An o…
2024
Additional file 1. The study protocol has been approved by the Clinical Study Review Board of Chiba University Hospital, Chiba, Japan, and registered by the Japan Registry of Clinical Trials (jRCTs032230278, https://jrct.niph.go.jp/ ). An o…
2024
Additional file 2. The participant consent form has been approved by the Clinical Study Review Board of Chiba University Hospital, Chiba, Japan, and registered by the Japan Registry of Clinical Trials (jRCTs032230278, https://jrct.niph.go.j…
2024
Additional file 2. The participant consent form has been approved by the Clinical Study Review Board of Chiba University Hospital, Chiba, Japan, and registered by the Japan Registry of Clinical Trials (jRCTs032230278, https://jrct.niph.go.j…
other
2024
Abstract Background Endometriosis-related pain encompassing dysmenorrhea, dyspareunia, and chronic pelvic pain, reduces the quality of life in premenopausal women. Although treatment options for endometriosis alleviate this pain, approximat…
other
2024
Abstract Background Endometriosis-related pain encompassing dysmenorrhea, dyspareunia, and chronic pelvic pain, reduces the quality of life in premenopausal women. Although treatment options for endometriosis alleviate this pain, approximat…
observational
2023
Although adenomyosis is reportedly associated with adverse pregnancy outcomes, clinical factors related to the high risk of obstetric complications are unclear. This study aimed to elucidate the characteristics of adenomyosis lesions associ…
observational
2023
Although adenomyosis is reportedly associated with adverse pregnancy outcomes, clinical factors related to the high risk of obstetric complications are unclear. This study aimed to elucidate the characteristics of adenomyosis lesions associ…
observational
2022
Additional file 1: Fig. S1. Kaplan-Meier survival analysis of endometrial cancer patients. A Progression-free survival rate according to the presence of concomitant endometriosis. B Overall survival rate according to the presence of concomi…
observational
2022
Additional file 1: Fig. S1. Kaplan-Meier survival analysis of endometrial cancer patients. A Progression-free survival rate according to the presence of concomitant endometriosis. B Overall survival rate according to the presence of concomi…
observational
2022
Abstract Background Endometriosis is assumed to be involved in ovarian cancer development, which is called endometriosis-associated ovarian cancer (EAOC). Uterine endometrial cells may be the cell of origin of EAOC. Accumulated carcinogenic…
observational
2022
Abstract Background Endometriosis is assumed to be involved in ovarian cancer development, which is called endometriosis-associated ovarian cancer (EAOC). Uterine endometrial cells may be the cell of origin of EAOC. Accumulated carcinogenic…
2021
Additional file 1. Demographic and baseline characteristics.
2021
Additional file 1. Demographic and baseline characteristics.
2021
Additional file 2. Change from baseline in mean of M-B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.
2021
Additional file 2. Change from baseline in mean of M-B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.
2021
Additional file 3. Change from baseline in mean of B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.
2021
Additional file 3. Change from baseline in mean of B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.
2021
Additional file 4. Results of other endpoints.
2021
Additional file 4. Results of other endpoints.
2021
Additional file 5. Summary of pharmacodynamic parameters at each assessment point.
2021
Additional file 5. Summary of pharmacodynamic parameters at each assessment point.
rct
2021
Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Method…
rct
2021
Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Method…
diagnostic-accuracy
2019
In cases of extragenital endometriosis or microscopic endometriosis lesions, pathological diagnosis can be challenging because endometriotic stroma and glands represent only a minor component of fibrotic endometriotic lesions. For better ac…